Table 4. Glucose-dependent insulinotropic peptide (GIP; pmol/L)

	100-300μ	300-500μ	Sham	100-300μ vs. 300-500μ (*p*)	100-300μ vs. Sham (*p*)	300-500μ vs. Sham (*p*)
T0	72.69±51.57	37.54±36.44	58.31±50.81	0.42	0.38	0.37
T1	98.79±15.05	68.71±76.31	94.99±41.60	0.42	0.43	0.47
T2	73.16±45.10	50.95±34.52	68.67±58.91	**0.03**	0.48	0.35
T3	58.14±17.60	28.22±14.93	71.44±30.28	0.09	0.26	0.06
T4	63.69±5.98	36.64±10.88	77.54±39.35	0.13	0.26	0.14
T0 vs. T1 (*p*)	0.18	0.43	0.15			
T0 vs. T2 (*p*)	0.49	0.28	0.4			
T0 vs. T3 (*p*)	0.3	0.14	0.35			
T0 vs. T4 (*p*)	0.2	0.18	0.3			
T2 vs. T3 (*p*)	0.29	0.13	0.47			
T2 vs. T4 (*p*)	0.2	0.22	0.41			
T3 vs. T4 (*p*)	0.35	0.19	0.42			

GIP levels are expressed in pmol/L. T0= before embolization; T1= after 1 hour; T2= after 1 month; T3= after 3 months; T4= after 6 months. Data are expressed as mean ± SD (standard deviation). A p value <0.05 was considered statistically significant.